# Neoadjuvant Exisulind in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage II or Stage III Prostate Cancer

> **NCT00078910** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 130 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** exisulind
- **PROCEDURE:** conventional surgery
- **PROCEDURE:** neoadjuvant therapy

## Key facts

- **NCT ID:** NCT00078910
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08
- **Primary completion:** —
- **Final completion:** 2006-09
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2013-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00078910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00078910, "Neoadjuvant Exisulind in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage II or Stage III Prostate Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00078910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*